These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9889213)

  • 41. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A reverse-transcription competitive PCR assay based on chemiluminescence hybridization for detection and quantification of hepatitis C virus RNA.
    Young KC; Chang TT; Hsiao WC; Cheng PN; Chen SH; Jen CM
    J Virol Methods; 2002 May; 103(1):27-39. PubMed ID: 11906730
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevation of viral load by PCR and use of plasma preparation tubes for quantification of human immunodeficiency virus type 1.
    García-Bujalance S; Ladrón de Guevara C; González-García J; Arribas JR; Zamora F; Gutiérrez A
    J Microbiol Methods; 2007 May; 69(2):384-6. PubMed ID: 17363096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV reverse transcriptase activity assay: a feasible surrogate for HIV viral load measurement in China.
    Huang D; Zhuang Y; Zhai S; Song Y; Liu Q; Zhao S; Wang S; Li X; Kang W; Greengrass V; Plate M; Crowe SM; Sun Y
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):208-13. PubMed ID: 20846816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the Amplicor HIV-1 monitor test and the nucleic acid sequence-based amplification assay for quantitation of human immunodeficiency virus RNA in plasma, serum, and plasma subjected to freeze-thaw cycles.
    Griffith BP; Rigsby MO; Garner RB; Gordon MM; Chacko TM
    J Clin Microbiol; 1997 Dec; 35(12):3288-91. PubMed ID: 9399536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitative assay for group M (subtype A-H) and group O HIV-1 RNA detection in plasma.
    Ernest I; Alexandre I; Zammatteo N; Herman M; Houbion A; De Leener F; Fransen K; van der Groen G; Remacle J
    J Virol Methods; 2001 Apr; 93(1-2):1-14. PubMed ID: 11311338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients.
    Leao JC; Kumar N; McLean KA; Porter SR; Scully CM; Swan AV; Teo CG
    J Med Virol; 2000 Dec; 62(4):416-20. PubMed ID: 11074468
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?
    Ripamonti D; Hill A; Lauthouwers E; van Delft Y; Moecklinghoff C
    AIDS Rev; 2013; 15(4):230-6. PubMed ID: 24322383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes.
    Holguín A; de Mendoza C; Soriano V
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):256-9. PubMed ID: 10385013
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma.
    Dyer JR; Pilcher CD; Shepard R; Schock J; Eron JJ; Fiscus SA
    J Clin Microbiol; 1999 Feb; 37(2):447-9. PubMed ID: 9889240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of low HIV-1 RNA levels in plasma.
    Schockmel GA; Yerly S; Perrin L
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):179-83. PubMed ID: 9052729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.
    Zolopa AR; Shafer RW; Warford A; Montoya JG; Hsu P; Katzenstein D; Merigan TC; Efron B
    Ann Intern Med; 1999 Dec; 131(11):813-21. PubMed ID: 10610625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reverse transcriptase activity for quantitation of HIV-1 subtype C in plasma: relation to RNA copy number and CD4 T-cell count.
    Seyoum E; Wolday D; Girma M; Malmsten A; Meselle T; Gronowitz JS; Britton S
    J Med Virol; 2006 Feb; 78(2):161-8. PubMed ID: 16372295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.
    Alteri C; Scutari R; Stingone C; Maffongelli G; Brugneti M; Falasca F; Martini S; Bertoli A; Turriziani O; Sarmati L; Coppola N; Andreoni M; Santoro MM; Perno CF; Ceccherini-Silberstein F; Svicher V
    J Clin Virol; 2019 Aug; 117():61-67. PubMed ID: 31229934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.
    Persaud D; Siberry GK; Ahonkhai A; Kajdas J; Monie D; Hutton N; Watson DC; Quinn TC; Ray SC; Siliciano RF
    J Virol; 2004 Jan; 78(2):968-79. PubMed ID: 14694128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Baxter JD; Mayers DL; Wentworth DN; Neaton JD; Hoover ML; Winters MA; Mannheimer SB; Thompson MA; Abrams DI; Brizz BJ; Ioannidis JP; Merigan TC
    AIDS; 2000 Jun; 14(9):F83-93. PubMed ID: 10894268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting.
    Rouet F; Ekouevi DK; Chaix ML; Burgard M; Inwoley A; Tony TD; Danel C; Anglaret X; Leroy V; Msellati P; Dabis F; Rouzioux C
    J Clin Microbiol; 2005 Jun; 43(6):2709-17. PubMed ID: 15956387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.